ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1067

Analysis of the Transcriptomic Profiles of Rheumatic Skin Diseases Reveals Disease-specific Endotypes

Sneha Shrotri1, Kathryn Kingsmore Allison1, Prathyusha Bachali2, Amrie Grammer3 and Peter Lipsky1, 1AMPEL BioSolutions, Charlottesville, VA, 2AMPEL BioSolutions, Redmond, WA, 3AMPEL LLC, Charlottesville, VA

Meeting: ACR Convergence 2022

Keywords: Bioinformatics

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Systemic Sclerosis and Related Disorders – Clinical Poster I

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Patients with rheumatic skin diseases such as cutaneous lupus erythematosus (CLE) and systemic sclerosis (SSc) can be classified from individuals with healthy skin using the enrichment of specific molecular signatures [1]. However, as patient heterogeneity is a well-known feature of these diseases, it is important to ascertain whether there are distinct patient molecular phenotypes (endotypes). Moreover, identifying specific disease endotypes from analysis of peripheral blood might increase the capacity to recognize patient endotypes.

Methods: Gene expression data derived from publicly available lesional skin biopsies of CLE, specifically discoid lupus erythematosus (DLE), the most severe CLE subtype, and SSc patients was analyzed using gene set variation analysis (GSVA) of informative gene modules. Paired blood samples were also analyzed when available. K-means clustering was then applied to the GSVA enrichment scores to identify molecular endotypes in both skin diseases.

Results: In DLE, k-means clustering revealed three subsets with distinct features (Fig. 1a). The least abnormal DLE cluster (blue) was characterized by minimal changes, including higher B cell GSVA scores, whereas the other two clusters (green and yellow) had markedly increased inflammatory cell and pathway gene expression, with most modules being enriched by a greater magnitude in yellow. In SSc, four endotypes emerged from k-means clustering (Fig. 1b). The first cluster (gold) was the least abnormal, with unchanged cell and metabolic signatures. The second cluster (orange) was characterized by increased melanocyte transcripts and altered metabolic signature expression. The third cluster (pink) exhibited increased myeloid, NK, T, and plasma cell signatures as well as increased glycolysis, pentose phosphate, and apoptosis signatures. The most severe SSc endotype (purple) was comprised of increased myeloid cell, T cell, and fibroblast signatures, and altered metabolism expression. Both the pink and purple clusters were enriched in cytokine signaling modules such as IL12 and TNF. Comparison of the three DLE endotypes with the four SSc endotypes revealed some overlap between the least severe clusters (blue and gold) of each disease (Fig. 1c). Finally, we examined the ability to predict SSc skin endotypes from the blood of paired samples. Blood was analyzed for enrichment of blood-specific gene signatures and then the blood samples were grouped into the SSc skin-identified clusters (Fig. 2a). The most severe SSc skin endotype could be predicted by Classification and Regression Tree (CART) analysis of blood, a negative plasmacytoid dendritic cell (pDC) GSVA score in the blood predicted the purple cluster (Fig. 2b).

Conclusion: Both DLE and SSc skin exhibit distinct subsets based upon their molecular profile (endotype). In addition, the most severe SSc skin subset can be identified from blood gene expression. Identifying specific molecular endotypes of patients with inflammatory skin disease may facilitate matching individual patients with effective therapies.

Supporting image 1

Figure 1. K-means clustering of CLE and SSc skin reveals molecular endotypes. K-means clustering of (a) DLE (GSE184989) and (b) SSc (GSE58095) using GSVA enrichment scores of cellular and pathway gene signatures. (c) Cosine similarity analysis to compare the molecular profiles of the endotypes derived from DLE to those of SSc.

Supporting image 2

Figure 2. SSc skin endotypes can be predicted from analysis of blood gene expression. (a) K-means clustering of blood from matched SSc patients (GSE179153) into the SSc skin-identified clusters. (b) CART classification of the purple (most severe) cluster using blood gene expression modules. P is the probability of identifying individual patients in the purple cluster.


Disclosures: S. Shrotri, None; K. Kingsmore Allison, None; P. Bachali, None; A. Grammer, None; P. Lipsky, None.

To cite this abstract in AMA style:

Shrotri S, Kingsmore Allison K, Bachali P, Grammer A, Lipsky P. Analysis of the Transcriptomic Profiles of Rheumatic Skin Diseases Reveals Disease-specific Endotypes [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/analysis-of-the-transcriptomic-profiles-of-rheumatic-skin-diseases-reveals-disease-specific-endotypes/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-the-transcriptomic-profiles-of-rheumatic-skin-diseases-reveals-disease-specific-endotypes/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology